Last edition
News about "asundexian FXIa inhibitor"
Center for Drug Evaluation accepts Bayer’s marketing authorisation application for FXIa inhibitor asundexian in stroke prevention, supported by phase 3 OCEANIC-STROKE data.
Asundexian FXIa Inhibitor | 30/04/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members